VIROLOGICAL STUDIES OF RECIPIENTS OF HIV-1 VACCINES

HIV-1亚单位疫苗(GP 160，Microgenesys)的第一阶段试验正在进行中 在NIAID的路上。DNA病毒研究实验室正在跟踪这些 从不同体液(唾液、唾液、 血、尿)。CMV的培养在之前和之后进行 定期接种疫苗。 该疫苗的第二次试验招募了无症状的HIV-1阳性患者 病人。希望这些患者体内CD_4细胞数量的稳定 患者将减少系统性巨细胞病毒的发生率。第三次审判 最近开始使用Microgenesys亚单位p24疫苗来 为HIV-1血清阳性的无症状患者接种疫苗。

Phase I trial of HIV-1 subunit vaccine (gp 160, Microgenesys), is under way at the NIAID. The laboratory of DNA Virus Research is following these vaccinees in terms of CMV isolation from different body fluids (saliva, blood, urine). Cultures of CMV are performed before and following vaccinations at regular time intervals. A second trial of this vaccine enrolled HIV-1 positive asymptomatic patients. It is hoped that stabilization of CD4 cell numbers in these patients will result in reduced incidence of sytemic CMV. A third trial has recently begun, using the Microgenesys subunit p24 vaccine to immunize HIV-1 seropositive asymptomatic patients.